Natco Pharma submits application with USFDA for generic cancer drug

The company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV' certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca's Olaparib tablets in strengths of 100mg and 150mg.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news